Nektar Therapeutics Reviews

2.9
Rating Trends
Recommend to a friend
Approve of CEO
Nektar Therapeutics President, CEO, and Director Howard W. Robin
Howard W. Robin
22 Ratings
  • Helpful (2)

    Research Scientist

    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Current Employee - Research Associate III in San Francisco, CA
    Current Employee - Research Associate III in San Francisco, CA
    Doesn't Recommend
    Neutral Outlook
    Approves of CEO

    I have been working at Nektar Therapeutics full-time (More than 5 years)

    Pros

    Benefits are good. Pay is solid. Work time is relatively flexible in terms of project development.

    Cons

    Leadership-focused culture and science foundation needs a lot of work to be done.

    Advice to Management

    Senior management team shall have direct and regular interaction with laboratory researchers, to know what they think and need to improve productivity.


Nektar Therapeutics Interviews

Interview Experience

Interview Experience

75%
12%
12%

Getting an Interview

Getting an Interview

57%
14%
14%
14

Interview Difficulty

2.9
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    QA Interview

    Anonymous Interview Candidate in San Francisco, CA
    Accepted Offer
    Positive Experience
    Average Interview

    Application

    I applied online. The process took 3+ months. I interviewed at Nektar Therapeutics (San Francisco, CA).

    Interview

    Good process, and very thorough; but took way too long to finally get an offer and start date.

    Interview Questions

    Negotiation

    Rigid, inflexible

Nektar Therapeutics Awards & Accolades

Something missing? Add an award
Best Places to Work for Commuters , National Center for Transit Research at USF, 2012

Additional Info

Unlock Profile
Website www.nektar.com
Headquarters San Francisco, CA
Size 150 to 499 Employees
Founded 1990
Type Company - Public (NKTR)
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Nektar Therapeutics has pegged its fortunes to making drugs more effective. The clinical-stage drug development firm uses its PEGylation technology, (based upon polyethylene glycol) to improve the delivery and efficacy of existing drugs. Nektar's pipeline is focused on anti-infectives and anti-virals, immunology, oncology, and pain treatments. Its lead candidate NKTR-118 (which it is developing in collaboration with AstraZeneca) is being tested as a treatment for opioid-induced constipation. It also maintains a handful of preclinical candidates. Nektar receives ... More

Work at Nektar Therapeutics? Share Your Experiences

Nektar Therapeutics

 
Click to Rate
or